Source: https://regulations.justia.com/regulations/fedreg/2019/06/11/2019-12266.html
Timestamp: 2019-08-18 02:52:41
Document Index: 273065177

Matched Legal Cases: ['art 812', 'art 812', 'art 812', '§ 812', '§ 812', '§ 812', 'art 812', 'art 812', 'art 812']

Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records, 27139-27141 [2019-12266] :: Food And Drug Administration :: Department Of Health And Human Services :: Regulation Tracker :: Justia
Justia Regulation Tracker Department Of Health And Human Services Food And Drug Administration Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records, 27139-27141 [2019-12266]
Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records, 27139-27141 [2019-12266]
Download as PDF Federal Register / Vol. 84, No. 112 / Tuesday, June 11, 2019 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2012–N–0477] Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on investigational device exemptions reports and records. DATES: Submit either electronic or written comments on the collection of information by August 12, 2019. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before August 12, 2019. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of August 12, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. khammond on DSKBBV9HB2PROD with NOTICES SUMMARY: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such VerDate Sep<11>2014 17:36 Jun 10, 2019 Jkt 247001 as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2012–N–0477 for ‘‘Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 27139 in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, PRAStaff@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) E:\FR\FM\11JNN1.SGM 11JNN1 27140 Federal Register / Vol. 84, No. 112 / Tuesday, June 11, 2019 / Notices ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Investigational Device Exemptions Reports and Records OMB Control Number 0910–0078— Extension Section 520(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360j(g)) establishes the statutory authority to collect information regarding investigational devices and establishes rules under which new medical devices may be tested using human subjects in a clinical setting. The Food and Drug Administration Modernization Act of 1997 (Pub. L. 105– 115) added section 520(g)(6) to the FD&C Act and permitted changes to be made to either the investigational device or to the clinical protocol without FDA approval of an investigational device exemption (IDE) supplement. An IDE allows a device, which would otherwise be subject to provisions of the FD&C Act, such as premarket notification or premarket approval, to be used in investigations involving human subjects in which the safety and effectiveness of the device is being studied. The purpose of part 812 (21 CFR part 812) is to encourage, to the extent consistent with the protection of public health and safety and with ethical standards, the discovery and development of useful devices intended for human use. The IDE regulation is designed to encourage the development of useful medical devices and allow investigators the maximum freedom possible, without jeopardizing the health and safety of the public or violating ethical standards. To do this, the regulation provides for different levels of regulatory control, depending on the level of potential risk the investigational device presents to human subjects. Investigations of significant risk devices, ones that present a potential for serious harm to the rights, safety, or welfare of human subjects, are subject to the full requirements of the IDE regulation. Nonsignificant risk device investigations, i.e., devices that do not present a potential for serious harm, are subject to the reduced burden of the abbreviated requirements. The regulation also includes provisions for treatment IDEs. The purpose of these provisions is to facilitate the availability, as early in the device development process as possible, of promising new devices to patients with life-threatening or serious conditions for which no comparable or satisfactory alternative therapy is available. Section 812.10 permits the sponsor of the IDE to request a waiver of any of the requirements of part 812. Sections 812.20, 812.25, and 812.27 describe the information necessary to file an IDE application with FDA. The submission of an IDE application to FDA is required only for significant risk device investigations. Section 812.20 lists the data requirements for the original IDE application, § 812.25 lists the contents of the investigational plan, and § 812.27 lists the data relating to previous investigations or testing. The information in the original IDE application is evaluated by the Center for Devices and Radiological Health to determine whether the proposed investigation will reasonably protect the public health and safety. Upon approval of an IDE application by FDA, a sponsor must submit certain requests and reports. Under § 812.35, a sponsor who wishes to make a change in the investigation that affects the scientific soundness of the study or the rights, safety, or welfare of the subjects, is required to submit a request for the change to FDA. Section 812.150 requires a sponsor to submit reports to FDA. These requests and reports are submitted to FDA as supplemental applications. This information is needed for FDA to assure protection of human subjects and to allow review of the study’s progress. Section 812.36(c) identifies the information necessary to file a treatment IDE application. FDA uses this information to determine if wider distribution of the device is in the interest of the public health. Section 812.36(f) identifies the reports required to allow FDA to monitor the size and scope of the treatment IDE, to assess the sponsor’s due diligence in obtaining marketing clearance of the device, and to ensure the integrity of the controlled clinical trials. Section 812.140 lists the recordkeeping requirements for investigators and sponsors. FDA requires this information for tracking and oversight purposes. Investigators are required to maintain records, including correspondence and reports concerning the study, records of receipt, use or disposition of devices, records of each subject’s case history and exposure to the device, informed consent documentation, study protocol, and documentation of any deviation from the protocol. Sponsors are required to maintain records including correspondence and reports concerning the study, records of shipment and disposition, signed investigator agreements, adverse device effects information, and, for a nonsignificant risk device study, an explanation of the nonsignificant risk determination, records of device name and intended use, study objectives, investigator information, investigational review board information, and statement on the extent that good manufacturing practices will be followed. For a nonsignificant risk device investigation, the investigators’ and sponsors’ recordkeeping and reporting burden is reduced. Pertinent records on the study must be maintained by both parties, and reports are made to sponsors and institutional review boards (IRBs). Reports are made to FDA only in certain circumstances, e.g., recall of the device, the occurrence of unanticipated adverse effects, and as a consequence of certain IRB actions. The estimate of the burden is based on the number of IDEs received in recent years. FDA estimates the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents khammond on DSKBBV9HB2PROD with NOTICES Activity/21 CFR section Number of responses per respondent Total annual responses Average burden per response Total hours Waivers—812.10 .................................................................. IDE Application—812.20, 812.25, and 812.27 .................... Supplements—812.35 and 812.150 .................................... Treatment IDE Applications—812.36(c) .............................. Treatment IDE Reporting—812.36(f) ................................... 1 229 654 1 1 1 1 5 1 1 1 229 3,270 1 1 1 80 6 120 20 1 18,320 19,620 120 20 Total .............................................................................. ........................ ........................ ........................ ........................ 38,081 1 There are no capital costs or operating and maintenance costs associated with this collection of information. VerDate Sep<11>2014 17:36 Jun 10, 2019 Jkt 247001 PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 E:\FR\FM\11JNN1.SGM 11JNN1 27141 Federal Register / Vol. 84, No. 112 / Tuesday, June 11, 2019 / Notices TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1 Number of recordkeepers Activity/21 CFR section Number of records per recordkeeper Total annual records Average burden per recordkeeping Total hours Original—812.140 ................................................................ Supplemental—812.140 ....................................................... Nonsignificant—812.140 ...................................................... 229 654 356 1 5 1 229 3,270 356 10 1 6 2,290 3,270 2,136 Total .............................................................................. ........................ ........................ ........................ ........................ 7,696 1 There are no capital costs or operating and maintenance costs associated with this collection of information. TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1 Activity/21 CFR section Number of respondents Number of disclosures per respondent Total annual disclosures Average burden per disclosure Total hours Reports for Nonsignificant Risk Studies—812.150 ............. 1 1 1 6 6 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Our estimated burden for the information collection reflects an overall decrease of 528 hours. We attribute this adjustment to a decrease in the number of submissions we received over the last few years. Dated: June 6, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–12266 Filed 6–10–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Opportunity To Collaborate on National Youth Sports Initiative To Increase Youth Sports Participation; Correction Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, President’s Council on Sports, Fitness, and Nutrition. ACTION: Notice of collaboration; correction. AGENCY: The Department of Health and Human Services published a document in the Federal Register of June 3, 2019, concerning the opportunity to collaborate on National Youth Sports Initiative to increase youth sports participation with the President’s Council on Sports, Fitness & Nutrition (PCSFN). The document contained an incorrect date. FOR FURTHER INFORMATION CONTACT: Ms. Holli M. Richmond, Executive Director, khammond on DSKBBV9HB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:36 Jun 10, 2019 Jkt 247001 Office of the President’s Council on Sports, Fitness, and Nutrition, Tower Building, 1101 Wootton Parkway, Suite 560, Rockville, MD 20852, (240) 276– 9567. Correction In the Federal Register of June 3, 2019, in FR Vol. 84 No. 106, on page 25548, in the third column, correct the DATES captions to read: DATES: To receive consideration, a request to participate as a collaborating organization must be received via email or postmarked mail at the addresses listed below, by 5:00 p.m. EST on Thursday, June 20, 2019. Dated: June 5, 2019. Holli M. Richmond, Executive Director, Office of the President’s Council on Sports, Fitness, and Nutrition, U.S. Department of Health and Human Services. [FR Doc. 2019–12251 Filed 6–10–19; 8:45 am] BILLING CODE 4150–36–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; The NIH Neurobiobank Brain and Tissue Repository. Date: June 12, 2019. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Vinod Charles, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892–9606, 301–443–1606, charlesvi@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: June 5, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–12224 Filed 6–10–19; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\11JNN1.SGM 11JNN1
[Pages 27139-27141]
[FR Doc No: 2019-12266]
[[Page 27139]]
Comment Request; Investigational Device Exemptions Reports and Records
notice solicits comments on investigational device exemptions reports
of information by August 12, 2019.
FDA-2012-N-0477 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Investigational Device Exemptions
Reports and Records.'' Received comments, those filed in a timely
[[Page 27140]]
OMB Control Number 0910-0078--Extension
Section 520(g) of the Federal Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 360j(g)) establishes the statutory authority to collect
information regarding investigational devices and establishes rules
under which new medical devices may be tested using human subjects in a
clinical setting. The Food and Drug Administration Modernization Act of
1997 (Pub. L. 105-115) added section 520(g)(6) to the FD&C Act and
permitted changes to be made to either the investigational device or to
the clinical protocol without FDA approval of an investigational device
exemption (IDE) supplement. An IDE allows a device, which would
otherwise be subject to provisions of the FD&C Act, such as premarket
notification or premarket approval, to be used in investigations
involving human subjects in which the safety and effectiveness of the
device is being studied. The purpose of part 812 (21 CFR part 812) is
to encourage, to the extent consistent with the protection of public
health and safety and with ethical standards, the discovery and
development of useful devices intended for human use. The IDE
regulation is designed to encourage the development of useful medical
devices and allow investigators the maximum freedom possible, without
jeopardizing the health and safety of the public or violating ethical
standards. To do this, the regulation provides for different levels of
regulatory control, depending on the level of potential risk the
investigational device presents to human subjects.
Investigations of significant risk devices, ones that present a
potential for serious harm to the rights, safety, or welfare of human
subjects, are subject to the full requirements of the IDE regulation.
Nonsignificant risk device investigations, i.e., devices that do not
present a potential for serious harm, are subject to the reduced burden
of the abbreviated requirements. The regulation also includes
provisions for treatment IDEs. The purpose of these provisions is to
facilitate the availability, as early in the device development process
as possible, of promising new devices to patients with life-threatening
or serious conditions for which no comparable or satisfactory
alternative therapy is available. Section 812.10 permits the sponsor of
the IDE to request a waiver of any of the requirements of part 812.
Sections 812.20, 812.25, and 812.27 describe the information necessary
to file an IDE application with FDA. The submission of an IDE
application to FDA is required only for significant risk device
investigations. Section 812.20 lists the data requirements for the
original IDE application, Sec.  812.25 lists the contents of the
investigational plan, and Sec.  812.27 lists the data relating to
previous investigations or testing. The information in the original IDE
application is evaluated by the Center for Devices and Radiological
Health to determine whether the proposed investigation will reasonably
Upon approval of an IDE application by FDA, a sponsor must submit
certain requests and reports. Under Sec.  812.35, a sponsor who wishes
to make a change in the investigation that affects the scientific
soundness of the study or the rights, safety, or welfare of the
subjects, is required to submit a request for the change to FDA.
Section 812.150 requires a sponsor to submit reports to FDA. These
requests and reports are submitted to FDA as supplemental applications.
This information is needed for FDA to assure protection of human
subjects and to allow review of the study's progress. Section 812.36(c)
identifies the information necessary to file a treatment IDE
application. FDA uses this information to determine if wider
distribution of the device is in the interest of the public health.
Section 812.36(f) identifies the reports required to allow FDA to
monitor the size and scope of the treatment IDE, to assess the
sponsor's due diligence in obtaining marketing clearance of the device,
and to ensure the integrity of the controlled clinical trials.
Section 812.140 lists the recordkeeping requirements for
investigators and sponsors. FDA requires this information for tracking
and oversight purposes. Investigators are required to maintain records,
including correspondence and reports concerning the study, records of
receipt, use or disposition of devices, records of each subject's case
history and exposure to the device, informed consent documentation,
study protocol, and documentation of any deviation from the protocol.
Sponsors are required to maintain records including correspondence and
reports concerning the study, records of shipment and disposition,
signed investigator agreements, adverse device effects information,
and, for a nonsignificant risk device study, an explanation of the
nonsignificant risk determination, records of device name and intended
use, study objectives, investigator information, investigational review
board information, and statement on the extent that good manufacturing
practices will be followed.
For a nonsignificant risk device investigation, the investigators'
and sponsors' recordkeeping and reporting burden is reduced. Pertinent
records on the study must be maintained by both parties, and reports
are made to sponsors and institutional review boards (IRBs). Reports
are made to FDA only in certain circumstances, e.g., recall of the
device, the occurrence of unanticipated adverse effects, and as a
consequence of certain IRB actions.
The estimate of the burden is based on the number of IDEs received
Activity/21 CFR section         Number of     responses per   Total annual   Average burden    Total hours
Waivers--812.10.................               1               1               1               1               1
IDE Application--812.20, 812.25,             229               1             229              80          18,320
and 812.27.....................
Supplements--812.35 and 812.150.             654               5           3,270               6          19,620
Treatment IDE Applications--                   1               1               1             120             120
812.36(c)......................
Treatment IDE Reporting--                      1               1               1              20              20
812.36(f)......................
Total.......................  ..............  ..............  ..............  ..............          38,081
[[Page 27141]]
Table 2--Estimated Annual Recordkeeping Burden 1
Activity/21 CFR section         Number of      records per    Total annual         per         Total hours
Original--812.140...............             229               1             229              10           2,290
Supplemental--812.140...........             654               5           3,270               1           3,270
Nonsignificant--812.140.........             356               1             356               6           2,136
Total.......................  ..............  ..............  ..............  ..............           7,696
Table 3--Estimated Annual Third-Party Disclosure Burden 1
Activity/21 CFR section                           Number of     disclosures per    Total annual    Average burden    Total hours
respondents       respondent      disclosures     per disclosure
Reports for Nonsignificant Risk Studies--812.150...................               1                1                1                6                6
overall decrease of 528 hours. We attribute this adjustment to a
decrease in the number of submissions we received over the last few